Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$12.35 - $26.11 $1.82 Million - $3.85 Million
147,639 New
147,639 $1.82 Million
Q4 2023

Feb 09, 2024

BUY
$12.64 - $30.11 $2.74 Million - $6.52 Million
216,503 New
216,503 $4.87 Million
Q3 2023

Nov 13, 2024

BUY
$16.64 - $25.32 $3.6 Million - $5.48 Million
216,503 New
216,503 $3.6 Million
Q3 2023

Nov 13, 2023

SELL
$16.64 - $25.32 $4.89 Million - $7.45 Million
-294,039 Closed
0 $0
Q2 2023

Aug 14, 2024

BUY
$21.59 - $27.88 $2.75 Million - $3.55 Million
127,446 Added 86.32%
275,085 $6.75 Million
Q2 2023

Aug 14, 2023

SELL
$21.59 - $27.88 $6.35 Million - $8.2 Million
-294,039 Closed
0 $0
Q1 2023

May 15, 2024

BUY
$23.46 - $36.44 $6.45 Million - $10 Million
275,085 New
275,085 $6.64 Million
Q4 2022

Feb 14, 2023

BUY
$27.82 - $44.16 $9.18 Million - $14.6 Million
330,042 New
330,042 $9.75 Million
Q3 2022

Nov 13, 2023

BUY
$16.33 - $51.06 $4.8 Million - $15 Million
294,039 New
294,039 $12.3 Million
Q2 2022

Aug 14, 2023

BUY
$17.22 - $38.47 $5.06 Million - $11.3 Million
294,039 New
294,039 $8.27 Million
Q1 2022

May 12, 2023

SELL
$32.6 - $53.05 $1.31 Million - $2.13 Million
-40,201 Reduced 12.18%
289,841 $10.8 Million
Q1 2022

May 09, 2022

SELL
$32.6 - $53.05 $9.45 Million - $15.4 Million
-289,841 Closed
0 $0
Q4 2021

Mar 09, 2022

BUY
$36.77 - $90.91 $10.7 Million - $26.3 Million
289,841 New
289,841 $12.7 Million
Q3 2021

Nov 14, 2022

BUY
$41.79 - $135.3 $12.1 Million - $39.2 Million
289,841 New
289,841 $18 Million

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $110M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Norges Bank Portfolio

Follow Norges Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.